REFERENCES
1. Long R, Zuo H, Tang G, et al. Antibody-drug conjugates in cancer therapy: applications and future advances. Front Immunol. 2025;16:1516419.
2. Agelidis A, Ter-Zakarian A, Jaloudi M. Triple-negative breast cancer on the rise: breakthroughs and beyond. Breast Cancer. 2025;17:523-9.
3. Zhu Y, Zhou S, Liu Y, Zhai L, Sun X. Prognostic value of systemic inflammatory markers in ovarian cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer. 2018;18:443.
4. Narayana RVL, Gupta R. Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment. Oncogene. 2025;44:2343-56.
5. Davis AA, Hesse J, Pereira PMR, Ma CX. Novel treatment approaches utilizing antibody-drug conjugates in breast cancer. NPJ Breast Cancer. 2025;11:42.
6. Zhang X, Xiao H, Na F, et al. Evolution of TROP2: biological insights and clinical applications. Eur J Med Chem. 2025;296:117863.
7. Bujnak AC, Solaru SA, Tewari K. Clinical applications of antibody drug conjugates for gynecologic malignancies: review of available medicines and emerging therapeutics. Gynecol Oncol. 2025;195:180-91.
8. Dri A, Arpino G, Bianchini G, et al. Breaking barriers in triple negative breast cancer (TNBC) - unleashing the power of antibody-drug conjugates (ADCs). Cancer Treat Rev. 2024;123:102672.
9. Fenton MA, Tarantino P, Graff SL. Sequencing antibody drug conjugates in breast cancer: exploring future roles. Curr Oncol. 2023;30:10211-23.
10. Gupta G, Hussain MS, Pant K, Ali H, Thapa R, Bhat AA. Antibody-drug conjugates (ADCs): a novel therapy for triple-negative breast cancer (TNBC). Curr Cancer Drug Targets. 2025;25:108-12.
11. García-Illescas D, Mazzeo R, García-Durán C, Oaknin A. The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era. Curr Opin Obstet Gynecol. 2024;36:104-11.
12. Veneziani AC, Sneha S, Oza AM. Antibody-drug conjugates: advancing from magic bullet to biological missile. Clin Cancer Res. 2024;30:1434-7.
13. Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315-37.
14. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183-9.
15. Dennis N, Dunton K, Livings C, et al. Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. Eur J Cancer. 2025;217:115192.
16. Wen M, Yu A, Park Y, Calarese D, Gerber HP, Yin G. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations. MAbs. 2025;17:2498162.
17. Murase Y, Nanjo S, Ueda T, et al. Mechanisms of resistance to antibody-drug conjugates in cancers. Respir Investig. 2025;63:693-8.
18. Saleh K, Khoury R, Khalife N, et al. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer. Cancer Drug Resist. 2024;7:22.
19. Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15:2825-34.
20. Monteiro MR, Nunes NCC, Junior AADS, et al. Antibody-drug conjugates in breast cancer: a comprehensive review of how to selectively deliver payloads. Breast Cancer. 2024;16:51-70.
21. García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody-drug conjugates. Cancer Res. 2018;78:2159-65.
22. Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020;25:4764.
23. Li G, Guo J, Shen BQ, et al. Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther. 2018;17:1441-53.
24. Larose ÉA, Hua X, Yu S, Pillai AT, Yi Z, Yu H. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. Cancer Drug Resist. 2025;8:11.
25. Kinneer K, Meekin J, Tiberghien AC, et al. SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads. Clin Cancer Res. 2018;24:6570-82.
26. Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 2021;11:2436-45.
27. Glaviano A, Wander SA, Baird RD, et al. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist Updat. 2024;76:101103.
28. Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol. 2009;37:755-66.
29. Zou Y, Yang A, Chen B, et al. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resist Updat. 2024;77:101126.
30. Rosen DB, Harrington KH, Cordeiro JA, et al. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One. 2013;8:e53518.
31. Zhang L, Romero P. Metabolic control of CD8+ T cell fate decisions and antitumor immunity. Trends Mol Med. 2018;24:30-48.
32. Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun. 2023;43:297-337.
33. Kepp O, Kroemer G. Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates. Oncoimmunology. 2025;14:2533488.
34. Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010;36:206-15.
35. Guven DC, Yildirim HC, Kus F, et al. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment. Expert Rev Anticancer Ther. 2023;23:1049-59.
36. Zou Y, Zhang H, Chen P, et al. Clinical approaches to overcome PARP inhibitor resistance. Mol Cancer. 2025;24:156.
37. Gao Y, Zhou J, Wang CC, et al. Novel ATR/PARP1 dual inhibitors demonstrate synergistic antitumor efficacy in triple-negative breast cancer models. Adv Sci. 2025;12:e01916.
38. Ye F, Dewanjee S, Li Y, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.
39. Gbadamosi MO, Molchan E, Makarem MS, Coleman KL, Ohaegbulam AC, Streeks KH. Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy. Oncoimmunology. 2025;14:2527303.
40. Bao W, Li Z. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer. Crit Rev Oncol Hematol. 2024;194:104238.
41. Aslan M, Hsu EC, Garcia-Marques FJ, et al. Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer. 2021;7:141.
42. Bignotti E, Todeschini P, Calza S, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010;46:944-53.
43. Khan S, Jandrajupalli SB, Bushara NZA, et al. Targeting refractory triple-negative breast cancer with sacituzumab govitecan: a new era in precision medicine. Cells. 2024;13:2126.
44. Qureshi Z, Jamil A, Altaf F, et al. Revolutionizing triple-negative metastatic breast cancer treatment: sacituzumab Govitecan’s role in advancing chemotherapy. Ann Med Surg. 2024;86:5314-9.
45. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423-33.
46. Bardia A, Punie K, Barrios C, et al. 275TiP ASCENT-03: phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2022;33:S663-4.
47. Marmé F, Hanusch C, Furlanetto J, et al. 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. Ann Oncol. 2022;33:S148-9.
48. Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;42:2860-72.
49. Santin AD, Corr BR, Spira A, et al. Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer. J Clin Oncol. 2024;42:3421-9.
50. Perrone E, Lopez S, Zeybek B, et al. Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer. Front Oncol. 2020;10:118.
51. Greenman M, Bellone S, Demirkiran C, Max Philipp Hartwich T, Santin AD. Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer. Gynecol Oncol Rep. 2024;54:101459.
52. Bardia A, Krop IE, Kogawa T, et al. Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol. 2024;42:2281-94.
53. Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329-40.
54. Schipilliti FM, Drittone D, Mazzuca F, La Forgia D, Guven DC, Rizzo A. Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer. Heliyon. 2024;10:e28385.
55. Oaknin A, Ang J, Rha S, et al. 714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study. Ann Oncol. 2024;35:S547-8.
56. Bardia A, Jhaveri K, Im SA, et al.; TROPION-Breast01 Investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025;43:285-96.
57. Dent RA, Cescon DW, Bachelot T, et al. TROPION-Breast02: datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023;19:2349-59.
58. Cheng Y, Yuan X, Tian Q, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front Oncol. 2022;12:951589.
59. Lorusso D, Mirza M, Martin-Babau J, et al. 793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005. Ann Oncol. 2024;35:S592.
60. Ouyang Q, Rodon J, Liang Y, et al. Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. J Hematol Oncol. 2025;18:61.
61. Yap T, Hamilton E, Bauer T, et al. 547P Rucaparib + sacituzumab govitecan (SG): initial data from the phase Ib/II SEASTAR study (NCT03992131). Ann Oncol. 2020;31:S476-7.
62. Bardia A, Sun S, Thimmiah N, et al. Antibody-drug conjugate sacituzumab govitecan enables a sequential TOP1/PARP inhibitor therapy strategy in patients with breast cancer. Clin Cancer Res. 2024;30:2917-24.
63. Seneviratne LC, Harnden KK, Blau S, et al. Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): updated phase 2 safety and efficacy results. J Clin Oncol. 2024;42:1091.
64. Rainey N, Joshi R, Chiu J, et al. A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC. J Clin Oncol. 2023;41:TPS1130.
65. Spring LM, Tolaney SM, Fell G, et al. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024;35:293-301.
66. Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. J Clin Oncol. 2025;43:LBA109.
67. Tolaney SM, DeMichele A, Takano T, et al. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol. 2024;20:2343-55.
68. Schmid P, Loi S, De la Cruz Merino L, et al. 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: a phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC). ESMO Open. 2024;9:103203.
69. Sharma P, Heldstab J, Yoder R, et al. Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC). J Clin Oncol. 2025;43:1094.
70. Kier MW, Moshier EL, Blank SV, et al. A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer. J Clin Oncol. 2025;43:TPS5623.
71. Dowlati A, Richardson D, Lorusso P, et al. 439TiP AVZO-021-1001: a first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors. Ann Oncol. 2024;35:S405.
72. Schmid P, Im S, Armstrong A, et al. BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC) - initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). J Clin Oncol. 2021;39:1023.
73. Bardia A, Pusztai L, Albain K, et al. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024;16:17588359241248336.
74. Schmid P, Oliveira M, O’Shaughnessy J, et al. TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2025;17:17588359251327992.
75. McArthur HL, Tolaney SM, Dent R, et al. TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol. 2025;17:17588359251316176.
